Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study.
Chronic myelomonocytic leukemia (CMML)
SEER
outcomes
registry
survival
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
15 Sep 2023
15 Sep 2023
Historique:
medline:
16
9
2023
pubmed:
16
9
2023
entrez:
15
9
2023
Statut:
aheadofprint
Résumé
Outcomes for chronic myelomonocytic leukemia (CMML) are insufficiently characterized at the population level. We analyzed epidemiological trends for patients between 2001 and 2017, focusing on age, sex, race, and long-term survivors. Using the Surveillance, Epidemiology, and End Results Program, we studied 3929 patients, in four time-period (tp) cohorts, based on year of diagnosis [2001-2004 (tp1); 2005-2009 (tp2); 2010-2013 (tp3); 2014-2017 (tp4)]. Stable incidence overall, male predominance, and higher incidence for White versus Black and 'Other' races were noted. Three-year relative survival (RS) increased from 27.9% to 36.9% between tp1 and tp4. The most pronounced increase occurred between tp1 and tp2. All subgroups generally experienced RS improvements over time, except notably Black patients. Improvements for patients aged 85+ (3-year RS 8.4-23.6% between tp1 and tp4) and increases in long-term survivors (5-year OS from 13.2-22.3%) were observed. Additional study is warranted to explore these associations, particularly for Black patients.
Identifiants
pubmed: 37715313
doi: 10.1080/10428194.2023.2252123
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM